Latest & greatest articles for Rivastigmine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Rivastigmine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Rivastigmine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Rivastigmine

1. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis (...) associated with initiating donepezil versus other cholinesterase inhibitors.We conducted a retrospective cohort study in Ontario, Canada, from 2002 to 2017. Participants were adults aged 66 years or older with a newly dispensed prescription for donepezil compared with rivastigmine or galantamine. The primary outcome was hospital admission with rhabdomyolysis (assessed using hospital diagnostic codes) within 30 days of a new prescription of a cholinesterase inhibitor. Odds ratios were estimated using

2019 EvidenceUpdates

2. Rivastigmine for Alzheimer's disease. (PubMed)

Rivastigmine for Alzheimer's disease. Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose (...) , was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA.To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type.We searched ALOIS, the Cochrane

Full Text available with Trip Pro

2015 Cochrane

3. Rivastigmine for Alzheimer's disease. (PubMed)

Rivastigmine for Alzheimer's disease. Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose (...) , was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA.To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type.We searched ALOIS, the Cochrane

2015 Cochrane

4. Rivastigmine 3M Health Care Ltd

Rivastigmine 3M Health Care Ltd EMA/58565/2014 EMEA/H/C/003824 EPAR summary for the public Rivastigmine 3M Health Care Ltd rivastigmine This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rivastigmine 3M Health Care Ltd. For practical information about using (...) Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist. What is Rivastigmine 3M Health Care Ltd and what is it used for? Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine. Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. Rivastigmine 3M Health Care Ltd

2014 European Medicines Agency - EPARs

5. Rivastigmine for vascular cognitive impairment. (PubMed)

Rivastigmine for vascular cognitive impairment. Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico-pathological processes: multi-infarct dementia, single strategic infarct dementia and subcortical dementia. Not all victims fulfil strict (...) criteria for dementia and may be significantly cognitively impaired without memory loss, when the term vascular cognitive impairment (VCI) is more useful. Currently, no established standard treatment for VCI exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that cholinesterase inhibitors - such as rivastigmine - which are beneficial in Alzheimer's disease, may also be beneficial for VCI.To assess the efficacy

Full Text available with Trip Pro

2013 Cochrane

6. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]

[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary (...) commission: rivastigmine patches and galantamine] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cologne: Institut fuer

2012 Health Technology Assessment (HTA) Database.

7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer?s disease (review of TA111): a systematic review and economic model The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content

2012 NIHR HTA programme

8. Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine

Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine Executive Summary 1 Translation of the executive summary of the final report “Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin” (Version 1.0; Status: 03.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports - Commission No. A09-05 Cholinesterase inhibitors in Alzheimer’s disease: supplementary commission rivastigmine patches and galantamine 1 Executive summary of final report A09-05 Version 1.0 Cholinesterase inhibitors – rivastigmine patches/galantamine 03.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cholinesterase inhibitors in Alzheimer’s disease: supplementary

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

10. Rivastigmine Actavis

Rivastigmine Actavis 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union 6 June 2011 EMA/454217/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Rivastigmine Actavis International nonproprietary name: Rivastigmine Procedure No. EMEA/H/C/2036 Assessment Report as adopted by the CHMP with all information (...) an application for Marketing Authorisation to the European Medicines Agency (EMA) for Rivastigmine Actavis, through the centralised procedure falling within the scope of the Article 3 (3) – ‘Generic of a Centrally authorised product’ of Regulation (EC) No. 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24/09/2009. The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which

2011 European Medicines Agency - EPARs

11. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. (PubMed)

Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Delirium is frequently diagnosed in critically ill patients and is associated with adverse outcome. Impaired cholinergic neurotransmission seems to have an important role in the development of delirium. We aimed to establish the effect of the cholinesterase inhibitor rivastigmine on the duration (...) of delirium in critically ill patients.Patients (aged ≥18 years) who were diagnosed with delirium were enrolled from six intensive care units in the Netherlands, and treated between November, 2008, and January, 2010. Patients were randomised (1:1 ratio) to receive an increasing dose of rivastigmine or placebo, starting at 0·75 mL (1·5 mg rivastigmine) twice daily and increasing in increments to 3 mL (6 mg rivastigmine) twice daily from day 10 onwards, as an adjunct to usual care based on haloperidol

Full Text available with Trip Pro

2010 Lancet

13. Rivastigmine (Exelon) transdermal patch: risk of medication errors

Rivastigmine (Exelon) transdermal patch: risk of medication errors Rivastigmine (Exelon) transdermal patch: risk of medication errors - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Rivastigmine (Exelon) transdermal patch: risk of medication errors Medication errors and inappropriate use of the rivastigmine transdermal patch have been reported, some of which resulted in overdose. Healthcare professionals should be aware of the correct use of rivastigmine, and should advise (...) patients and caregivers as outlined in this article. Published 11 December 2014 From: Therapeutic area: Contents Rivastigmine (Exelon) transdermal patch is indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia. The patch is available in two doses: 4.6 mg/24 hours; and 9.5 mg/24 hours. Treatment is started with one 4.6 mg/24 hour patch. After a minimum of 4 weeks and if tolerated well, the daily dose should be increased to the recommended effective dose of 9.5 mg/24

2010 MHRA Drug Safety Update

14. Rivastigmine for dementia in people with Down syndrome. (PubMed)

Rivastigmine for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Rivastigmine is a "pseudo-irreversible" inhibitor of acetylcholinesterase, which is thought to maintain levels of acetylcholine. Rivastigmine can improve cognitive function and slow the decline of AD in the general population (...) over time. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety of rivastigmine for people with DS who develop AD.CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted

2009 Cochrane

15. Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer?s

Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer?s Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: rivastigmine reduces rate of cognitive decline and improves performance in mild to moderate Alzheimer’s Article Text Therapeutics Review: rivastigmine reduces

2009 Evidence-Based Mental Health

16. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

17. Rivastigmine - Dementia (Alzheimer's type)

Rivastigmine - Dementia (Alzheimer's type) CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION RIVASTIGMINE PATCH (Exelon ™ Patch – Novartis Pharmaceuticals Canada Inc.) Description: Exelon ™ Patch contains rivastigmine, a reversible cholinesterase inhibitor that is approved for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. Dosage Forms: Exelon Patch 5 contains 9 mg/5 cm 2 and releases 4.6 mg/24 hours. Exelon Patch 10 (...) -related adverse events when compared with placebo. 3. The Committee had concerns regarding the cost-effectiveness of Exelon Patch relative to best supportive care. Summary of Committee Considerations: The Committee considered a systematic review of double-blind randomized controlled trials (RCTs) in patients with mild to moderate dementia of the Alzheimer’s type. One trial of 24 weeks duration comparing Exelon Patch 10 with oral rivastigmine 6 mg given twice daily or placebo met the inclusion criteria

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

18. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

2008 DARE.

19. Exelon Patch (rivastigmine transdermal system)

Exelon Patch (rivastigmine transdermal system) Drug Approval Package: Exelon NDA #022083 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Exelon Patch (rivastigmine transdermal system) Company: Novartis Pharmaceuticals Corporation Application No.: 022083 Approval Date: 7/6/2007 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) Pharmacology Review

2007 FDA - Drug Approval Package

20. Rivastigmine three times daily improves cognition and response in Alzheimer’s disease

Rivastigmine three times daily improves cognition and response in Alzheimer’s disease Rivastigmine three times daily improves cognition and response in Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rivastigmine three times daily improves cognition and response in Alzheimer’s disease Article Text Therapeutics Rivastigmine three times daily improves cognition and response in Alzheimer’s disease Statistics from

2007 Evidence-Based Mental Health